Klaria Pharma (KLAR) Q2 2024 earnings summary

Executive summary

• No net sales were recorded in Q2 2024, with a continued focus on R&D and advancing the product pipeline.

• Sumatriptan Alginate Film received marketing authorization in Germany, Italy, and Spain after the period, marking a major milestone.

• The company is pursuing license agreements to cover all major European markets and aims to finance operations until product sales begin.

Financial highlights

• Net sales for Q2 2024 and H1 2024 were SEK 0.0 million, down from SEK 6.5 million in H1 2023.

• Profit after tax for Q2 2024 was SEK -12.4 million (Q2 2023: SEK -10.1 million); H1 2024 was SEK -24.3 million (H1 2023: SEK -15.5 million).

• R&D expenses for Q2 2024 were SEK 0.5 million (Q2 2023: SEK 7.0 million); H1 2024 was SEK 1.5 million (H1 2023: SEK 15.6 million).

• Cash and cash equivalents at June 30, 2024, were SEK 0.5 million (June 30, 2023: SEK 8.9 million).

• Equity at June 30, 2024, was SEK 20.8 million (June 30, 2023: SEK 60.6 million).

Outlook and guidance

• Focus remains on signing license agreements for Sumatriptan Alginate Film in Europe to secure financing until product sales commence.

• Plans to expand marketing authorization to additional European countries in 2025 and potentially apply for US approval.

• Ongoing partner-funded R&D projects with expected updates in 2024.